Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
03 May 2022 - 6:31AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company today
announced a poster presentation highlighting the Company’s
membrane-bound interleukin-15 (mbIL-15) program as a potentially
potent cell therapy targeting hotspot mutations expressed in solid
tumors at the 25th Annual Meeting of the American Society of Gene
and Cell Therapy being held in Washington, D.C. and virtually May
16-19, 2022.
“We are excited at the opportunity to present
new preclinical data in our mbIL-15 program at the ASGCT Annual
Meeting. In this study we observed the potential of our Sleeping
Beauty transposed mbIL-15 TCR-T cells to deepen clinical responses
and improve durability of TCR-T cells targeting hotspot mutations
expressed in solid tumors,” stated Drew Deniger, Ph.D., Vice
President, Research & Development at Alaunos Therapeutics. “We
continue to be encouraged by the data and intend to file an IND
application for this program in the second half of 2023.”
Details of the poster presentation are as
follows:
Poster Presentation: Stem-cell
memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens
generated through co-expression of membrane-bound
Interleukin-15Session Title: Cancer - Targeted
Gene and Cell Therapy ISession Date/Time: Monday
May 16, 2022, 5:30 PM - 6:30 PM ESTPoster Board
Number: M-234Location: Walter E.
Washington Convention Center, Hall
D Alaunos’ mbIL-15
program has been developed to augment the function of TCR-T cells
by co-expression of a more potent and proprietary membrane-bound
interleukin-15. In this preclinical study, Alaunos observed that
mbIL-15 TCR-T cells specifically targeted and killed tumors
expressing matching neoantigen and HLAs with negligible off target
effects. Furthermore, Alaunos observed the potential of mbIL-15 to
establish long-lived tumor-specific TCR-T cells that have the
potential to survive within the circulation and the tumor
microenvironment.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has clinical and strategic
collaborations with The University of Texas MD Anderson Cancer
Center and the National Cancer Institute. For more information,
please visit www.alaunos.com.
Forward-Looking Statements
Disclaimer This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as “may,” “will,” “could,” “expects,” “plans,”
“anticipates,” “believes” or other words or terms of similar
meaning. These statements include, but are not limited to,
statements regarding the Company's business and strategic plans,
the Company's ability to raise capital, and the timing of the
Company's research and development programs, including the
anticipated timing for regulatory filings and for enrolling and
dosing patients in the Company’s clinical trials. Although the
management team of Alaunos believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Alaunos,
that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include, among other things, changes in the Company’s
operating plans that may impact its cash expenditures; the
uncertainties inherent in research and development, future clinical
data and analysis, including whether any of Alaunos’ product
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for
which indication; the strength and enforceability of Alaunos’
intellectual property rights; and competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with the Securities
and Exchange Commission made by Alaunos, including those risks and
uncertainties listed in the most recent Form 10-Q and Form 10-K
filed by Alaunos with the Securities and Exchange Commission.
Alaunos is providing this information as of the date of this press
release, and Alaunos does not undertake any obligation to update or
revise the information contained in this press release whether as a
result of new information, future events, or any other reason.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2024 to May 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From May 2023 to May 2024